Tag Archives: NASDAQ:NBI

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what caused the carnage. There are many factors at

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits